Abstract Background/Aims: Atherosclerotic renal artery stenosis (ARAS) is frequently detected in patients with resistant hypertension (RHTN), but the evidence supporting the utility of renal revascularization in these patients is limited. This prospective, observational study investigates the outcomes of renal stenting in patients with RHTN and hemodynamically significant ARAS. Methods: Fifty-four patients with RHTN were selected because of angiographic evidence of ARAS >70% and were followed for 4 years after renal stenting. Renal function and echocardiographic variables were assessed at baseline and during follow-up. Results: Blood pressure decreased rapidly after renal stenting and was normalized in 67% of patients at six months, with significant reduction in the number of antihypertensive drugs. Creatinine clearance increased in 39% of patients, decreased in 52%, and remained stable in the remaining 9%, with an average value that had a nonsignificant decrease during follow-up. Urinary albumin excretion did not change throughout the study. After 4 years, left ventricular (LV) wall thickness and concentric geometry decreased significantly and variables of LV diastolic function improved. Conclusion: In patients with RHTN, stenting of hemodynamically significant ARAS decreases blood pressure, preserves renal function in a substantial proportion of patients, and improves LV structure and function, suggesting the opportunity for timely identification of ARAS in these patients.
Long-Term Renal and Cardiac Outcomes after Stenting in Patients with

Introduction
Hypertension is defined as resistant to treatment when two antihypertensive agents plus a diuretic at adequate doses fail to lower blood pressure values below 140/90 mm Hg. Resistant hypertension has a prevalence that approximates 10% within the overall hypertensive population [1] and is associated with a relatively more severe cardiac and renal damage [2, 3] . Resistant hypertension might originate from different conditions including characteristics of lifestyle, obstructive sleep apnoea, advanced hypertensive organ damage, and previously undetected forms of secondary hypertension [4] . Among the latter conditions, chronic renal failure, primary aldosteronism and renovascular hypertension (RVH) caused by atherosclerotic renal artery stenosis (ARAS) are the most frequent. The prevalence of ARAS in the elderly population is comprised from 5 to 10% [5] and steadily increases in patients undergoing different types of angiographic examinations [6] . In addition to RVH, a possible consequence of ARAS is ischemic nephropathy that might be a relevant cause of renal failure [7] and need for dialysis [8] . For these reasons, timely identification and correction of ARAS might modify the natural history of the disease with possible benefits for both renal and cardiovascular outcomes [9] . However, while a multiplicity of observational studies on revascularization of stenotic renal arteries reported a significant reduction in blood pressure and plasma creatinine, randomized controlled trials that compared renal artery angioplasty with stenting to conservative treatment did not meet the expectations as they could not demonstrate any benefit on renal and cardiovascular outcomes [10] . These randomized trials have been criticized on several grounds and principally for inadequate selection of patients [11] . Indeed, the majority of these studies enrolled patients with a relatively mild degree of renal arterial narrowing or excluded patients at higher cardiovascular risk such as those with resistant hypertension. Although ARAS is frequently detected in patients with resistant hypertension [12] , the evidence supporting the clinical utility of renal artery revascularization in these patients is limited because none of the previous studies focused on these specific patients and data currently available originate mostly from subgroup analyses. Moreover, only a few studies have examined in these patients the possible benefits of renal artery revascularization on hypertension-related cardiac changes and albuminuria. The aim of the present study was therefore to investigate prospectively and in the long-term the clinical, cardiac, and renal outcome of renal revascularization in patients with resistant hypertension and angiographic evidence of hemodynamically significant ARAS.
Materials and Methods
Patients Fifty-four patients (age 69±9 y.; 39 males, 15 females) with resistant hypertension and hemodynamically relevant ARAS detected at renal artery angiography were included in a long-term, observational, prospective study on the effects of renal revascularization with angioplasty and stenting. Patients were consecutively recruited between January 2002 and December 2011 among patients with hypertension resistant to treatment who were referred for evaluation at the Hypertension clinic of the University of Udine. Blood pressure was measured in the sitting position by a validated automated device (Omron M6, OMRON Healthcare Co., Kyoto, Japan) after each patient had been supine for 15 min and the average of three readings obtained in 5 min was recorded [13] . Resistant hypertension was defined according to established guidelines when systolic blood pressure was ≥140 mm Hg and/or diastolic blood pressure was ≥90 mm Hg in patients who were treated with three or more different antihypertensive agents that included a diuretic, at appropriate doses [13] . Predefined exclusion criteria were age younger than 40 years or older than 80 years, renal failure with 24-hour creatinine clearance ≤30 ml/min/1.73 m 2 , urinary protein excretion ≥0.5 g/day, congestive heart failure, and any other known renal disease. In all patients, pseudo-resistance (nonadherence to medication, white-coat hypertension, lifestyle) was ruled out with standardized procedures. To investigate the cause of resistant hypertension, all patients seen at the clinic are routinely screened with clinical and laboratory testing that include analysis of medical records and adherence to treatment, physical examination, urine analysis, blood biochemistries, duplicate measurements of 24-hour creatinine clearance and urinary sodium excretion, plasma active renin and aldosterone, urinary cortisol and catecholamines, electrocardiogram, echocardiography, polysomnography, renal ultrasound with duplex Doppler examination of intrarenal vessels, and renal angio-CT scan or angio-MRI [14] . Renal angiography was performed in all patients in whom increased intrarenal duplex systolic velocity was detected and/or renal artery stenosis was demonstrated either at angio-MRI or angio-CT scan [15] . Patients were classified as smokers if they had smoked for at least 5 years, and up to 1 year before the study. Dyslipidemia was defined by a non-HDL cholesterol ≥130 mg/dl and/or as current use of lipid-lowering medication [16] . Prevalence of coronary heart, cerebrovascular, and peripheral artery disease was also defined in all patients, as previously reported [17] .
Prospective study Hemodynamically significant ARAS was defined by angiographic demonstration of renal artery stenosis >70% in one or more major renal vessels [18] and was detected in 54 patients. Patients with lesser degrees of renal artery narrowing were excluded. No patient had angiographic characteristics of fibromuscular dysplasia or other types of renal artery disease. All the patients included in the prospective study were white, lived in the north-east of Italy, and were representative of the hypertensive population in this area [19] . Patients underwent renal artery revascularization by performing angioplasty with bare metal stenting of the stenotic renal artery. All procedures were performed by femoral approach according to standard interventional techniques. In patients with bilateral stenoses, both vessels were treated in a single procedure. Procedural success was defined as residual stenosis of less than 20%. Before the procedure, combined oral antiplatelet therapy was begun with aspirin (325 mg) and clopidogrel (300 mg). All patients were subsequently assigned to continuous treatment with aspirin (125 mg q.d.) with addition of clopidogrel (75 mg q.d.) for the first 6 months. Clinical and biochemical evaluations were performed after revascularization at 3 weeks, 6 months and 4 years. Antihypertensive treatment was adjusted to reach blood pressure values ≤140/90 mm Hg in quarterly visits during the first year and in yearly visits thereafter. Angiotensin-converting enzyme inhibitors or angiotensin II-receptor antagonists were used as the initial therapeutic choice with subsequently ordered addition of a thiazide diuretic, a dihydropyridine calcium-channel blocker, and a beta-blocker. The study was conducted in accordance with the principles of the Declaration of Helsinki and received approval from the Institutional Review Board. Informed consent was obtained from all patients.
Echocardiography
Cardiac ultrasound examination was performed by the same experienced operator who was unaware of the patients' clinical and laboratory characteristics [20] . Measurements of left ventricular (LV) internal dimensions and wall thickness were obtained with the patient in the partial left decubitus position with a commercial machine (Aplio CV, Toshiba Medical System, Tokyo, Japan) and a 2.5 MHz transducer, under bi-dimensional cross-sectional control and simultaneous electrocardiographic tracing. The LV geometric pattern was defined by the ratio of end-diastolic posterior LV wall thickness to one-half end-diastolic LV internal dimension (RWT). LV mass index (LVMI) was calculated by the Penn Convention formula and normalized for body surface area. Systolic function was estimated by the ejection fraction (EF) and both endocardial and midwall fractional shortening (FS), with the latter taking into account epicardial migration of the midwall during systole. Pulsed Doppler recordings at the level of the mitral valve tips were obtained from apical four-chambers scans to measure early and late wave diastolic filling velocities, their ratio (E/A ratio), early-wave deceleration time, and isovolumic relaxation time.
Laboratory measurements
A sample of venous blood was obtained from each patient in the sitting position in the morning after an overnight fast and without venous stasis. Blood was collected into silicone-treated glass tubes, where it was mixed with 10% of its volume of 0.1 mmol/l tri-sodium citrate and immediately centrifuged at 1, 700g for 20 min at 4°C. Plasma was separated and frozen at -80 °C until being assayed, usually within one month after sampling. Plasma lipids measurement was performed as reported previously [21] . Plasma concentrations of lipoprotein(a) were determined by the Macra® Lp(a) Enzyme Linked Immunosorbent Assay (ELISA) kit (Trinity Biotech PLC, Bray, Ireland) [21] . Active renin was assayed without previous antihypertensive drug washout by chemiluminescence enzyme immunoassay (CLIA) and plasma aldosterone was assayed by radioimmunoassay in plasma samples that were obtained with patients in the sitting position [22] . Creatinine clearance was assessed by duplicate 24-hour collections and normalized for body surface area. Albuminuria was measured in duplicate 24-hour urine collections by immunoturbidimetric method using a commercial kit with an analyzer ALBT2 (Tina-quant Albumin Gen.2, Roche/Hitachi, Mannheim, Germany) [23] . The limit of detection was 3 mg/l and the coefficient of variation between 0.7% and 1.9%.
Statistical analysis
Data are presented as mean ± SD for variables with normal distribution and as median (inter-quartile range) for skewed variables. Normally distributed variables were compared with the Student's t test. Variables with skewed distribution were analysed after logarithmic transformation. One-way analysis of variance was used to compare variables at different time-points after renal revascularization. Relationships between continuously distributed variables were examined by linear regression analysis. Two-tailed probability value of less than 5% was considered to indicate statistical significance. All data analyses were performed using Stata 9.2 (StataCorp LP, TX, USA).
Results
Five-hundred-sixty-eight patients with true resistant hypertension were screened at the clinic from January 2002 to December 2011. In 54 patients evidence of ARAS >70% was detected by angiography. Among patients with ARAS, 2 had bilateral stenosis and the remaining 52 had unilateral stenosis of the main renal artery. The clinical characteristics and comorbidities of patients with ARAS are shown in Table 1 . A relevant proportion of patients smoked and had dyslipidemia and/or diabetes. More than one third of patients had coronary artery and/or peripheral artery disease as comorbidities.
None of the patients was lost at follow-up. Both systolic (-17 mm Hg; 11%) and diastolic (-9 mm Hg; 9%) blood pressure decreased significantly 3 weeks after renal artery stenting and further significant decrease was observed at six months ( the long-term follow-up when blood pressure was normalized in 48 (89%) patients. Plasma renin levels decreased significantly 3 weeks after renal revascularization and did not change significantly thereafter, whereas plasma aldosterone levels did not change significantly throughout the study. No significant changes were observed in plasma glucose, lipids, and uric acid levels during follow-up. After renal artery revascularization, 24-h creatinine clearance increased in 21 (39%) patients, decreased in 28 (52%) and remained stable in the remaining 5 (9%) with an average value that had a small and nonsignificant decrease at the end of follow-up. Urinary albumin excretion did not change significantly in any patient throughout the study. Echocardiographic variables of patients with ARAS that were measured at baseline and during follow-up are summarized in Table 3 . No significant changes in LV internal dimensions, mass, geometry, systolic and diastolic function were observed at 6 months after renal artery revascularization. At the end of the long-term follow-up, interventricular septum and LV posterior wall thickness were significantly reduced and the average LV mass index was decreased but not significantly (-10 g/m 2 ). Also, the LV RWT was significantly decreased indicating reversal of the concentric pattern of LV geometry. No significant changes were observed in LV systolic function, whereas a significant reduction of left atrial diameter and increase in the E/A ratio indicated significant improvement of the LV diastolic function.
Univariate correlation analysis was used to examine the possible relationships between clinical (age, BMI, blood pressure, duration of hypertension) and biochemical (plasma glucose, lipids, uric acid, renin, aldosterone, creatinine clearance) variables that were measured at baseline and the changes in blood pressure, echocardiographic, and renal variables that were observed after renal artery revascularization. This analysis did not detect any significant relationships.
Discussion
Results of randomized clinical trials indicate that revascularization of ARAS does not confer any significant benefit over medical therapy [10, 24] . However, these trials have been broadly criticized because of criteria used for patients' selection and, as suggested by many observational studies, timely identification and treatment of ARAS might modify the natural history of disease at least in some of these patients. The challenge is therefore to define which patients with ARAS will potentially benefit from renal artery revascularization in terms of renal and cardiovascular protection [25] and specifically designed observational investigations could provide insight in specific groups of patients. The present study has been the first designed specifically to investigate the effects of renal artery stenting in patients with resistant hypertension and hemodynamically significant (>70%) ARAS free of advanced renal failure and overt proteinuria. Patients were followed with a rigorous protocol with standardized antihypertensive medications and long-term follow-up providing evidence of significant and persistent benefit on blood pressure levels. Creatinine clearance and urinary albumin excretion remained unchanged after renal artery revascularization whereas, in the long-term, hypertension-related cardiac abnormalities were affected by treatment with significant decrease of LV wall thickness and concentric geometry, and improvement of LV diastolic function.
Previous retrospective and prospective observational studies reported the benefits of renal artery revascularization in terms of blood pressure decrease and renal protection in patients with ARAS ≥50% [26, 27] even when this was associated with uncontrolled hypertension [28] [29] [30] . In a registry of 265 patients with angiographic evidence of ARAS ≥50%, a subgroup of whom had uncontrolled systolic hypertension, average blood pressure fell in a follow-up of 2 years from 160/86 mm Hg to 135/75 mm Hg [28] . Approximately half of patients in the registry had improved glomerular filtration suggesting that renal revascularization could preserve renal function in a substantial proportion. The HERCULES trial examined prospectively 202 patients with ARAS, 70% of whom had uncontrolled blood pressure (≥140/90 mm Hg) despite being on 3 or more antihypertensive agents [29] . In a 3-year follow-up, systolic blood pressure decreased by 16 mm Hg with no changes in the average number of antihypertensive drugs. However, in a retrospective analysis of 32 patients with refractory hypertension and ARAS ≥50% who underwent renal artery revascularization, Ritchie et al. did not observe any benefit on mortality, cardiovascular events, or end-stage renal disease during a follow-up of 3.8 years, in comparison to patients treated conservatively [30] . Additional observational studies lasting from 6 to 15 months examined the renal outcome of renal artery revascularization of ARAS in patients without resistant hypertension and reported a significant decrease in blood pressure levels with no changes in glomerular filtration [26, 27] or urinary albumin excretion [31, 32] . The results of the present prospective study further support the benefits on blood pressure control and preservation of renal function that can be obtained with renal artery stenting and extends the evidence to patients with hemodynamically significant ARAS who were identified because of resistant hypertension.
Cross-sectional investigations have demonstrated that hypertension-related cardiac abnormalities are significantly more frequent in patients with renal artery stenosis than matched patients with essential hypertension [33, 34] . Moreover, longitudinal assessment of cardiac structural and functional changes in patients with ARAS who were treated conservatively for 1 year demonstrated progression of these changes despite significant decrease in blood pressure [35] . Past studies addressed the effects of renal artery revascularization in hypertensive patients with renal artery stenosis (either ARAS or fibromuscular dysplasia) detected at angiography. Symonides et al. reported significant reduction of LV mass in 44 patients with either ARAS or fibromuscular dysplasia who underwent either surgical or percutaneous revascularization [31] . Similar reduction of LV mass was reported after renal artery stenting by Rzeznik et al [36] . and Zeller et al [37] . in a 1-year and 2-year follow-up study, respectively. Our study was conducted in patients with resistant hypertension and ARAS and demonstrates that successful renal artery stenting is followed, in the long-term, by reduction of LV mass that is associated with significant improvement of LV diastolic function.
Only a critical degree of renal artery stenosis can cause renal ischemia sufficient to activate the renin-angiotensin system and thereby hypertension, eventually leading to renal impairment. Although there is no established consensus on the degree of renal artery stenosis that justifies revascularization, the majority of previous observational and randomized studies used a 50% diameter stenosis as inclusion criterion [10] . However, it is known that due to compensatory intrarenal hemodynamics occurrence of reduced renal perfusion pressure with subsequent activation of the renin-angiotensin system requires renal arterial narrowing of more than 70% [38] . For these reasons the present study included only patients with this degree of renal artery stenosis. Moreover, the evidence of a hemodynamically relevant stenosis in our patients was supported by the demonstration of highly significant reduction of plasma renin levels that despite use of antihypertensive agents, occurred 3 weeks after renal stenting.
Some limitations of this study need to be highlighted. First, this is an observational study and, as such, cannot provide any insight on the value of renal stenting in comparison to conservative treatment. Second, use of a clinic sample might limit the possibility to extend conclusions to a more general setting because of a possible bias due to the referral of patients to the source of care. Third, because we did not find any associations between clinical and biochemical variables measured at baseline and changes in blood pressure and echocardiographic variables observed after renal stenting, statistical limitations in detection of these associations due to the size of the study (beta-error) cannot be excluded. Last, systematic use of ambulatory blood pressure monitoring during follow-up would have been useful to obtain better assessment of blood pressure changes induced by treatment. The strengths of this study include inclusion of a selected population of patients with resistant hypertension and evidence of hemodynamically significant ARAS, the rigorous treatment protocol that was used after renal stenting, and the duration of follow-up.
Conclusion
In patients with hypertension resistant to treatment and evidence of hemodynamically significant ARAS renal stenting decreases blood pressure, preserves renal function in a substantial proportion of patients, and improves LV structure and function in the longterm. These results indicate that negative results of randomized controlled trials of renal stenting performed in settings different from resistant hypertension should not withheld proper diagnostic evaluation for possible ARAS in these patients. Timely identification and correction of ARAS in patients with resistant hypertension could modify the natural history of the disease with significant benefits for both renal and cardiovascular outcomes.
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